EUCTR2016-000323-43-GB进行中（未招募）1 期
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination with Durvalumab versus Nivolumab Monotherapy in Subjects with Select Advanced Malignancies
MedImmune, LLC, a wholly-owned subsidiary of AstraZeneca PLC0 个研究点目标入组 96 人开始时间: 2016年9月9日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 96
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Must be 18 years or older
- •-Eastern Cooperative Oncology Group performance status of 0-1
- •-Adequate organ function
- •-No more than 1 prior line of therapy
- •For complete list of inclusion criteria please refer to the protocol
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 36
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •-Concurrent enrollment in another clinical study, unless in follow-up period or it is an observational study
- •-Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment
- •-Prior treatment with immunotherapy
- •For complete list of exclusion criteria please refer to the protocol
研究者
相似试验
进行中（未招募）
1 期
A clinical trial in patients with renal cell cancer that have had at least one, but no more than three prior cancer treatments and their cancer has gotten worse or did not respond. The study is investigating the safety, tolerability, and clinical activity of investigational drugs MEDI0680 and Durvalumab. The study will look at the effect of these two drugs when given to patients in combination (given together) versus nivolumab given alone.EUCTR2016-000323-43-NLMedImmune, LLC, a wholly-owned subsidiary of AstraZeneca PLC96
招募中
1 期
A First-in-Human, Open-label, Phase 1/2 Study of BOS-342 in Patients with Hepatocellular Carcinoma (HCC) and other Glypican 3 (GPC3)-expressing TumorsHepatocellular Carcinoma (HCC)Other GPC3-expressing TumorsCancer - LiverACTRN12623000798662Boston Pharmaceuticals, Inc.81
已完成
2 期
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination with Durvalumab versus Nivolumab Monotherapy in Subjects with Select Advanced Malignancies10038364clear-cell renal cell carcinoma (ccRCC)kidney cancerNL-OMON47649MedImmune, LLC, a wholly-owned subsidiary of AstraZeneca PLC10
进行中（未招募）
1 期
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory MyopathyActive Idiopathic Inflammatory Myopathy including dermatomyositis, anti-synthetase syndrome, and immune-mediated necrotizing myopathyMusculoskeletal DiseasesISRCTN75158615Advanced Clinical18
进行中（未招募）
1 期
A Study of Modakafusp Alfa in Combination With Daratumumab Subcutaneous in Patients With Relapsed/Refractory Multiple MyelomaMultiple MyelomaEUCTR2022-002169-14-ESTakeda Development Center Americas, Inc.58